{
    "clinical_study": {
        "@rank": "78781", 
        "acronym": "RA", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1", 
                "arm_group_type": "Experimental", 
                "description": "Orencia Group is for RA patients who have not received any other biologic treatment, including abatacept previously, and whose doctor has determined that it is appropriate to treat their RA with Abatacept. If you are in Group 1, you will receive the study drug, Abatacept, given in an intravenous (IV - injected into a vein) as well as subcutaneous form. Abatacept, given in an intravenous injection is approved by the FDA for the treatment of RA."
            }, 
            {
                "arm_group_label": "Arm 2 or group 2", 
                "arm_group_type": "Other", 
                "description": "Arm 2 or Group 2 is for RA patients who are being treated wth non-biologic DMARDS who, with their doctor, have decided that they will not be receiving treatment with Abatacept in the next six months. These patients will not receive the study drug abatacept."
            }
        ], 
        "brief_summary": {
            "textblock": "This proposal will test the hypothesis that Orencia affects apoptosis and apoptosis related\n      genes/biomarkers in vivo in rheumatoid arthritis (RA) patients."
        }, 
        "brief_title": "Effect on Orencia (Abatacept) on the Apoptosis of T Cells, B Cells and APC Cells in Rheumatoid Arthritis", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Apoptotic DNA Damage", 
            "Rheumatoid Arthritis", 
            "T-cell Lymphocytosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid", 
                "Lymphocytosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Orencia may regulate apoptosis and apoptosis related genes in vivo in rheumatoid arthritis\n      (RA) patient's cells. To date, no studies have been performed to evaluate the effect of\n      Orencia on apoptosis in RA patients.\n\n      Primary: To determine the effect of Abatacept in the apoptosis of T cells, B cells and\n      antigen presenting cells (APC) in RA patients at baseline, 3 months and 6 months.\n\n      Secondary: To evaluate the association between the changes in apoptosis to changes in\n      disease activity measures (DAS28/ESR) over 6 months of treatment with subcutaneous injection\n      of abatacept."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Over age 18\n\n          2. Meeting ACR Criteria 1987 for RA diagnosis\n\n          3. Na\u00efve to treatment with abatacept\n\n          4. Must be able to understand information in the Informed Consent\n\n        Exclusion Criteria:\n\n          1. Pregnancy or breast feeding\n\n          2. Previous exposure to abatacept.\n\n          3. History of a concomitant autoimmune disease (eg. SLE, PsA etc.)\n\n          4. Patients with history of cancer"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01717846", 
            "org_study_id": "IM101-356", 
            "secondary_id": "IM101-356"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm 1", 
                "description": "Group 1 subjects will be given subcutaneous abatacept, 125 mg once a week upto 6 months.", 
                "intervention_name": "Group 1 or Orencia treated group", 
                "intervention_type": "Drug", 
                "other_name": "Abatacept"
            }, 
            {
                "arm_group_label": "Arm 2 or group 2", 
                "description": "Arm 2 or Group 2 is for RA patients who are being treated wth non-biologic DMARDS who, with their doctor, have decided that they will not be receiving treatment with Abatacept in the next six months. These patients will not receive the study drug abatacept.", 
                "intervention_name": "Group 2 (DMARDS treated group)", 
                "intervention_type": "Other", 
                "other_name": "Arm 2 or group 2"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Abatacept", 
                "Antirheumatic Agents"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Apoptosos", 
            "Rheumatoid Arthritis", 
            "T cells, B cells", 
            "DAS28", 
            "Clinical Disease activity Index", 
            "CDAI"
        ], 
        "lastchanged_date": "October 30, 2012", 
        "location": {
            "contact": {
                "email": "mitaylor@mednet.ucla.edu", 
                "last_name": "Mihaela Taylor, MD", 
                "phone": "310-825-6301"
            }, 
            "contact_backup": {
                "email": "abenartzi@mednet.ucla.edu", 
                "last_name": "Ami B Artzi, MD", 
                "phone": "310-825-6301"
            }, 
            "facility": {
                "address": {
                    "city": "Los Angeles", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90095"
                }, 
                "name": "Univerity of California at Los Angeles"
            }, 
            "investigator": {
                "last_name": "John Fitz Gerald, MD, Ph.D.", 
                "role": "Sub-Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "In Vivo Effect on Orencia (Abatacept) on the Apoptosis of T Cells, B Cells and Antigen Presenting (APC) Cells in Rheumatoid Arthritis", 
        "other_outcome": {
            "description": "To measure the Clinical Disease Activity Index (CDAI), and Health Assessment Questionnaire (HAQ)", 
            "measure": "To measure the  change in  clinical disease activity index  between base line, at 3 months and 6 months time points.", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline, 3 and 6 months"
        }, 
        "overall_contact": {
            "email": "rpsingh@mednet.ucla.edu", 
            "last_name": "Ram P Singh, MS, Ph.D.", 
            "phone": "310 267 5749"
        }, 
        "overall_contact_backup": {
            "email": "mitaylor@mednet.ucla.edu", 
            "last_name": "Mihaela Taylor, MD", 
            "phone": "310-825-6301"
        }, 
        "overall_official": [
            {
                "affiliation": "University of California at Los Angeles, UCLA", 
                "last_name": "Ram P Singh, MS, Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of California at Los Angeles (UCLA)", 
                "last_name": "Mihaela Taylor, MD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To determine the effect of Abatacept in the apoptosis of T cells, B cells and antigen presenting cells (APC) in RA patients at baseline, 3 months and 6 months.", 
            "measure": "To measure the change in apoptosis of T cells, B cells and antigen presenting (APC) cells in Rheumatoid Arthritis between the baseline, 3 months and at 6 months time points", 
            "safety_issue": "No", 
            "time_frame": "Base line, 3 and 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01717846"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of California, Los Angeles", 
            "investigator_full_name": "Ram Singh", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "To measure the changes in disease activity score joint count (DAS28/ESR)", 
            "measure": "To measure the change in  disease activity score (DAS28) between the baseline, 3 months and 6 months time points", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline, 3 and 6 months"
        }, 
        "source": "University of California, Los Angeles", 
        "sponsors": {
            "collaborator": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University of California, Los Angeles", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}